Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Oct 15, 2021

SELL
$13.07 - $18.84 $2.23 Million - $3.22 Million
-170,708 Closed
0 $0
Q2 2021

Jul 06, 2021

BUY
$16.52 - $20.4 $676,180 - $834,992
40,931 Added 31.54%
170,708 $2.93 Million
Q1 2021

Apr 14, 2021

BUY
$16.56 - $25.46 $10,946 - $16,829
661 Added 0.51%
129,777 $2.6 Million
Q4 2020

Feb 04, 2021

BUY
$15.77 - $19.03 $144,374 - $174,219
9,155 Added 7.63%
129,116 $2.2 Million
Q3 2020

Nov 06, 2020

SELL
$16.59 - $24.79 $337,772 - $504,724
-20,360 Reduced 14.51%
119,961 $1.99 Million
Q2 2020

Aug 26, 2020

SELL
$16.86 - $23.44 $8,463 - $11,766
-502 Reduced 0.36%
140,321 $3.25 Million
Q1 2020

May 14, 2020

BUY
$14.47 - $27.96 $32,311 - $62,434
2,233 Added 1.61%
140,823 $2.51 Million
Q4 2019

Feb 12, 2020

BUY
$15.87 - $23.12 $1.62 Million - $2.36 Million
101,956 Added 278.31%
138,590 $2.99 Million
Q3 2019

Oct 23, 2019

SELL
$16.91 - $36.27 $758,971 - $1.63 Million
-44,883 Reduced 55.06%
36,634 $667,000
Q2 2019

Jul 15, 2019

BUY
$31.0 - $36.3 $225,711 - $264,300
7,281 Added 9.81%
81,517 $2.9 Million
Q1 2019

May 14, 2019

BUY
$31.58 - $46.35 $400,434 - $587,718
12,680 Added 20.6%
74,236 $2.49 Million
Q4 2018

Feb 08, 2019

SELL
$30.43 - $56.65 $92,994 - $173,122
-3,056 Reduced 4.73%
61,556 $2.02 Million
Q3 2018

Nov 14, 2018

BUY
$46.46 - $68.49 $1.89 Million - $2.78 Million
40,617 Added 169.27%
64,612 $3.94 Million
Q2 2018

Jul 27, 2018

SELL
$46.25 - $104.45 $149,988 - $338,731
-3,243 Reduced 11.91%
23,995 $1.17 Million
Q1 2018

May 08, 2018

BUY
$57.4 - $108.44 $1.3 Million - $2.45 Million
22,603 Added 487.66%
27,238 $2.89 Million
Q4 2017

Feb 27, 2018

BUY
$23.02 - $60.5 $106,697 - $280,417
4,635
4,635 $277,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $219M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Advisor Net Financial, Inc Portfolio

Follow Advisor Net Financial, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Net Financial, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Advisor Net Financial, Inc with notifications on news.